Werewolf Therapeutics (HOWL) Research & Development (2020 - 2026)

Werewolf Therapeutics (HOWL) has reported Research & Development for 7 consecutive years, with $6.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 53.12% year-over-year to $6.2 million in Q2 2026; TTM through Jun 2026 was $32.9 million, a 39.63% decrease from a year earlier, with the FY2025 full-year figure at $44.8 million, down 20.56% from the prior year.
• Research & Development was $6.2 million for Q2 2026 at Werewolf Therapeutics, down from $8.2 million in the prior quarter.
• Over five years, Research & Development peaked at $15.9 million in Q4 2022 and troughed at $6.2 million in Q2 2026.
• A 5-year average of $11.7 million and a median of $12.1 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 127.22% in 2022 and slumped 55.92% in 2025, its largest moves.
• Over 5 years, Research & Development stood at $15.9 million in 2022, then sank by 39.16% to $9.6 million in 2023, then surged by 62.99% to $15.7 million in 2024, then tumbled by 55.92% to $6.9 million in 2025, then retreated by 11.12% to $6.2 million in 2026.
• The last three Research & Development figures came in at $6.2 million (Q2 2026), $8.2 million (Q1 2026), and $6.9 million (Q4 2025), per Business Quant data.